CIPLA Cipla Q3 FY26 results (Oct–Dec 2025) and concall
Cipla navigated a challenging quarter marked by the completion of generic Revlimid decline and supply disruptions, while executing strategic growth initiatives including partnerships with Pfizer, acquisition of Inzpera, and successful product launches in diabetes care.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 9.5%, net profit down 57.1% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 4,971 | 4,798 | 5,046 | 5,226 | 4,498 −10% |
| EBITDA | 1,662 | 1,319 | 1,624 | 1,523 | 721 −57% |
| Net profit | 1,438 | 1,485 | 1,303 | 1,211 | 617 −57% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
